ZyVersa Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accounting Fees and Services
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
| Type of Fees | 2024 | 2023 |
|---|---|---|
| Audit Fees (1)(2) | $290,775 | $848,160 |
| Audit-Related Fees (3) | - | - |
| Tax Fees (4) | - | - |
| All Other Fees | - | - |
| Total | $290,775 | $848,160 |
| (1) | Audit fees are fees for professional services rendered in connection with the audit of our consolidated financial statements, statutory filings and registration statements, review of interim financial statements, the review of documents filed with the SEC, comfort letters, consents and certain accounting and consultations in connection with the audits. |
| (2) | Audit fees for the years ended December 31, 2024 and 2023 include professional fees incurred by Ernst and Young of $56,775 and $663,160, respectively, and Marcum of $234,000 and $185,000, respectively. |
| (3) | Audit-related fees are fees for services related to accounting consultation and compliance with regulatory requirements and are not reported under “Audit Fees”. |
| (4) | Tax fees are for services related to tax compliance, tax planning and tax advice. These services included annual U.S. federal and state compliance and preparation of related tax returns and reports. |
Pre-Approval Policies and Procedures
The audit committee has the authority and responsibility to pre-approve all audit, review, and non-audit services (including any internal control-related services) to be provided to us or our subsidiaries by the independent auditor. The audit committee may also establish pre-approval policies and procedures in compliance with applicable SEC rules. The pre-approval of services may be delegated to subcommittees of the audit committee consisting of one or more of the audit committee’s members, but the decision must be reported to the full audit committee at its next scheduled meeting.
All services rendered by EY and Marcum for the year ended December 31, 2023, and by Marcum for the year ended December 31, 2024, were pre-approved in accordance with the procedures set forth above.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.